The Indian Pharmaceutical Industry is One of the Fast Growing Sectors of the Indian...
The Indian Pharmaceutical Industry is One of the Fast Growing Sectors of the Indian Economy and Has Made Rapid Strides over the Years DUBLIN, Ireland--(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/reports/c83368) has announced the addition of "Indian Pharmaceutical Industry - SWOT Framework Analysis" to their offering. From being an import dependent industry in the 1950s, the Indian Pharmaceutical Industry has achieved self-sufficiency and gained global recognition as a producer of low cost high quality bulk drugs and formulations. Leading Indian companies have developed infrastructure in over 60 countries including developed markets like US and Europe. In the recent past, several pharmaceutical companies have demonstrated that they possess the ability to engage in commercially viable research and development activities and become significant players in the international market. SWOT Analysis, is a strategic planning tool used to evaluate the Strengths, Weaknesses, Opportunities, and Threats involved in a project or in a business venture. It involves specifying the objective of the business venture or project and identifying the internal and external factors that are favorable and unfavorable to achieving that objective. The aim of any SWOT analysis is to identify the key internal and external factors that are important to achieving the objective. SWOT analysis groups key pieces of information into two main categories: Internal factors - The strengths and weaknesses internal to the organization. External factors - The opportunities and threats presented by the external environment. -0- *T Report Topics Executive Summary Brief Profile of the Industry SWOT Framework Analysis - Strengths to Build Upon - Weaknesses to Overcome - Opportunities to Exploit - Threats to Overcome Glossary of Terms *T For more information visit here Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com Fax: +353 1 4100 980 Copyright Business Wire 2008
© Thomson Reuters 2008 All rights reserved






